½ÃÀ庸°í¼­
»óǰÄÚµå
1462837

¼¼°èÀÇ À§Ç³¼± ½ÃÀå ±Ô¸ð Á¶»ç ¹× ¿¹Ãø : Á¦Ç° À¯Çüº°, Åõ¿© ¹æ¹ýº°, ÃæÀü Àç·áº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ºÐ¼®(2023-2030³â)

Global Intragastric Balloon Market Size Study & Forecast, by Product Type, By Administration, By Filling Material, By End-user, and Regional Analysis, 2023-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Bizwit Research & Consulting LLP | ÆäÀÌÁö Á¤º¸: ¿µ¹® 200 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ À§Ç³¼± ½ÃÀåÀº 2022³â¿¡ ¾à 3,920¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, ¿¹Ãø ±â°£ÀÎ 2023-2030³â¿¡´Â 13.9% ÀÌ»óÀÇ °ÇÀüÇÑ ¼ºÀå·ü·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù.

À§Ç³¼±Àº ºñ¸¸À¸·Î °íÅë¹Þ´Â »ç¶÷µéÀÇ Ã¼Áß °¨·®À» µ½±â À§ÇØ °í¾ÈµÈ ÀÇ·á±â±âÀÔ´Ï´Ù. ÀÔ¿¡¼­ À§Àå¿¡ »ðÀԵǴ ºÎµå·¯¿î ½Ç¸®ÄÜ Ç³¼±Àº ¸ê±Õ ½Ä¿°¼ö·Î ä¿öÁø ºÎµå·¯¿î ½Ç¸®ÄÜ Ç³¼±À¸·Î Æ÷¸¸°¨À» ÁÖ¾î À½½Ä ¼·Ã븦 ÁÙÀÔ´Ï´Ù. ½Ã¼úÀº ÃÖ¼Ò Ä§½ÀÀûÀ̸ç ÀϽÃÀûÀ¸·Î ³»½Ã°æÀ» ÅëÇØ ÀÌ·ç¾îÁý´Ï´Ù. ¶ÇÇÑ Ç³¼±Àº ´õ °Ç°­ÇÑ ½Ä½À°ü°ú »ýȰ½À°ü º¯È­¸¦ ÃËÁøÇϰí ÀÇ·áÁøÀÇ °¨µ¶ÇÏ¿¡ Áö¿ø Á¶Ä¡·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÃÖ¼Ò Ä§½ÀÀû Ä¡·áÀÇ Ã¤Åà Áõ°¡, À§Ç³¼± ½ÂÀÎ Áõ°¡, ÀÇ·áºñ »ó½ÂÀº Àü ¼¼°è ½ÃÀå ¼ö¿ä¸¦ ÁÖµµÇÏ´Â °¡Àå µÎµå·¯Áø ¿äÀÎÀÔ´Ï´Ù. ¹Ì±¹ ±¹¸³»ý¹°°øÇÐÁ¤º¸¼¾ÅÍ(NCBI)°¡ 2023³â 1¿ù¿¡ ¹ßÇ¥ÇÑ ¿¬±¸¿¡ µû¸£¸é À§Ç³¼±Àº ºñ¸¸ À§±â¸¦ ÇØ°áÇϱâ À§ÇÑ ÃÖ¼Òħ½ÀÀû ¼Ö·ç¼ÇÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¹Ì±¹°ú À¯·´ ½ÃÀå¿¡¼­ ¿©·¯ °³ÀÇ À§Ç³¼±ÀÌ ½ÂÀεǾúÀ¸¸ç, ±× ±âÁØÀº BMI°¡ ¹Ì±¹¿¡¼­ 30-35kg/m2, À¯·´¿¡¼­ 27-35kg/m2·Î ´Ù¾çÇÕ´Ï´Ù.

¶ÇÇÑ À§Ç³¼±»ðÀÔ¼úÀº ¿Ü°úÀû ¼ö¼ú¿¡ ºñÇØ ¾ÈÀüÇÏ°í ºñ¿ë ´ëºñ È¿°ú°¡ ³ô¾Æ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é 2022³â ÇöÀç Àü ¼¼°è ºñ¸¸ À¯º´·üÀº ¿ì·ÁÇÒ ¸¸ÇÑ ¼öÁØ¿¡ À̸£·¶À¸¸ç, Àü ¼¼°è Àα¸ 8¸í Áß 1¸íÀÌ ºñ¸¸À» ¾Î°í ÀÖ½À´Ï´Ù. ¼ºÀÎ ºñ¸¸À²Àº 1990³â ÀÌÈÄ 2¹è ÀÌ»ó, û¼Ò³â ºñ¸¸À²Àº °°Àº ±â°£ 4¹è ÀÌ»ó Áõ°¡ÇßÀ¸¸ç, 18¼¼ ÀÌ»ó ¼ºÀÎ Áß ¾à 25¾ï ¸íÀÌ °úüÁßÀ¸·Î ºÐ·ùµÇ°í, 8¾ï 9,000¸¸ ¸íÀÌ ºñ¸¸ ¹üÁÖ¿¡ ¼ÓÇÕ´Ï´Ù. ÀÌ´Â ¼ºÀÎÀÇ 43%°¡ °úüÁßÀ̰í 16%´Â ºñ¸¸°ú °øÁ¸Çϰí ÀÖ´Ù´Â °ÍÀ» ÀǹÌÇÕ´Ï´Ù. ¶ÇÇÑ 5¼¼ ¹Ì¸¸ÀÇ °úüÁß ¾Æµ¿Àº 3,700¸¸ ¸í, 5¼¼¿¡¼­ 19¼¼ »çÀÌÀÇ ¾Æµ¿ ¹× û¼Ò³âÀº 3¾ï 9,000¸¸ ¸í ÀÌ»óÀÌ °úüÁßÀ̸ç, ±× Áß 1¾ï 6,000¸¸ ¸íÀÌ ºñ¸¸°ú °øÁ¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Åë°è´Â ¿¬·É´ë¸¦ ÃÊ¿ùÇÑ ºñ¸¸ À¯Çà¿¡ ´ëóÇϰí À̸¦ ÅðÄ¡Çϱâ À§ÇÑ Àü ¼¼°èÀûÀÎ ³ë·ÂÀÌ ½Ã±ÞÈ÷ ÇÊ¿äÇÏ´Ù´Â °ÍÀ» °­Á¶ÇÕ´Ï´Ù. À§Ç³¼±Àº ºñ¸¸ Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ¾î È¿°úÀûÀÎ °á°ú¸¦ °¡Á®¿Ô½À´Ï´Ù. µû¶ó¼­ Àü ¼¼°è ºñ¸¸ À¯º´·ü Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ºñ¸¸Àº ½ÉÇ÷°ü Áúȯ, ´ç´¢º´, ³úÁ¹Áß, °íÇ÷¾Ð, ƯÁ¤ ¾Ï°ú °°Àº ´Ù¾çÇÑ ºñÀü¿°¼º Áúȯ°ú °ü·ÃÀÌ ÀÖÀ¸¸ç, ÀÌ´Â Àü ¼¼°è Á¤ºÎ°¡ ºñ¸¸ °ü¸®¿¡ ´ëÇÑ ÀνÄÀ» ³ôÀ̵µ·Ï Ã˱¸Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÎ½Ä Á¦°í Ä·ÆäÀÎÀº À§Ç³¼± äÅÃÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ Ç³¼± ±â¼úÀÇ ¹ßÀü°ú ´õºÒ¾î »ýȰ½À°ü Áß½ÉÀÇ Ã¼Áß °ü¸®¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÇâÈÄ ¼ö³â°£ ´Ù¾çÇÑ ºñÁî´Ï½º ±âȸ°¡ âÃâµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª À§Ç³¼± ½Ã¼ú°ú °ü·ÃµÈ ÇÕº´Áõ, À§Çè ¹× »óȯ ºÎÁ·Àº 2023-2030³âÀÇ ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¼¼°èÀÇ À§Ç³¼± ½ÃÀå Á¶»ç¿¡¼­ °í·ÁµÈ ÁÖ¿ä Áö¿ªÀº ¾Æ½Ã¾ÆÅÂÆò¾ç, ºÏ¹Ì, À¯·´, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÔ´Ï´Ù. ºÏ¹Ì´Â ºñ¸¸ÀÇ È®»ê, ¼÷·ÃµÈ Àü¹®°¡ÀÇ Á¸Àç, üÁß °¨·® Ä¡·áÀÇ »ó´çÇÑ Ã¤ÅÃÀ¸·Î ÀÎÇØ 2022³â ½ÃÀåÀ» Àå¾ÇÇß½À´Ï´Ù. ¶ÇÇÑ À§Ç³¼±ÀÇ Àα⠻ó½Â°ú äÅÃÀÌ ÀÌ Áö¿ªÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº ¿¹Ãø ±â°£ Áß °¡Àå ³ôÀº CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ȯÀÚ Àα¸ Áõ°¡, »õ·Î¿î ±â¼ú¿¡ ´ëÇÑ ÀÇ·á Àü¹®°¡¿Í ȯÀÚÀÇ ÀÎ½Ä Áõ°¡, ´Ù¾çÇÑ Ã¼Áß °¨·® ÇÁ·Î±×·¥ÀÇ µµÀÔÀº ÀÌ Áö¿ª Àüü ½ÃÀå ¼ö¿ä¸¦ Å©°Ô ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 7¿ù Allurion Technologies, Inc.´Â À§ dz¼± üÁß °¨·® ÇÁ·Î±×·¥ÀÎ Elipse¸¦ µµÀÔÇÏ¿© ¾Æ½Ã¾Æ Áö¿ª¿¡¼­ÀÇ ÀÔÁö¸¦ È®´ëÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

ÀÌ Á¶»ç ¸ñÀûÀº ÃÖ±Ù ´Ù¸¥ ºÎ¹®°ú ±¹°¡ÀÇ ½ÃÀå ±Ô¸ð¸¦ Á¤ÀÇÇϰí, ÇâÈÄ ¼ö³â°£ °¡Ä¡¸¦ ¿¹ÃøÇÏ´Â °ÍÀÔ´Ï´Ù. Á¶»ç ´ë»ó±¹³» »ê¾÷ÀÇ ÁúÀû¡¤¾çÀû Ãø¸é ¾çÃøÀ» Æ÷ÇÔ½Ã۵µ·Ï ¼³°èµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ ½ÃÀåÀÇ ÇâÈÄ ¼ºÀåÀ» ±ÔÁ¤ÇÏ´Â ÃËÁø¿äÀÎ ¹× °úÁ¦ µîÀÇ Áß¿äÇÑ Ãø¸é¿¡ °üÇÑ »ó¼¼ Á¤º¸µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÁÖ¿ä ±â¾÷ÀÇ °æÀï ±¸µµ ¹× Á¦Ç° Á¦°øÀÇ »ó¼¼ ºÐ¼®°ú ÇÔ²² ÀÌÇØ°ü°èÀÚ°¡ ÅõÀÚÇϱâ À§ÇÑ ¹Ì½ÃÀû ½ÃÀåÀÇ ÀáÀçÀû ±âȸµµ Æ÷ÇÔÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼¼°èÀÇ À§Ç³¼± ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§

  • Á¶»ç ¸ñÀû
  • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
    • ¾÷°èÀÇ ÁøÈ­
    • Á¶»ç ¹üÀ§
  • Á¶»ç ´ë»ó³â
  • ÅëÈ­ ȯ»êÀ²

Á¦3Àå ¼¼°èÀÇ À§Ç³¼± ½ÃÀå ¿ªÇÐ

  • À§Ç³¼± ½ÃÀåÀÇ ¿µÇ⠺м®(2020-2030³â)
    • ½ÃÀå ÃËÁø¿äÀÎ
      • Àúħ½ÀÄ¡·áÀÇ Ã¤Åà Áõ°¡
      • ºñ¸¸ÀÇ Áõ°¡
    • ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
      • À§Ç³¼± ½Ã¼ú¿¡ °ü·ÃµÈ ÇÕº´Áõ°ú ¸®½ºÅ©
      • »óȯÀÇ °á¿©
    • ½ÃÀå ±âȸ
      • dz¼± ±â¼úÀÇ Áøº¸
      • ¶óÀÌÇÁ½ºÅ¸ÀÏÀ» Áß½ÃÇÑ Ã¼Áß °ü¸®ÀÇ Á߿伺 Áõ°¡

Á¦4Àå ¼¼°èÀÇ À§Ç³¼± ½ÃÀå »ê¾÷ ºÐ¼®

  • Porter's Five Forces ¸ðµ¨
    • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
    • ±¸¸ÅÀÚÀÇ ±³¼··Â
    • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • Porter's Five Forces ¿µÇ⠺м®
  • PEST ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ȯ°æ
    • ¹ý·ü
  • ÁÖ¿ä ÅõÀÚ ±âȸ
  • ÁÖ¿ä ¼º°ø Àü·«
  • COVID-19 ¿µÇ⠺м®
  • ÆÄ±«Àû µ¿Çâ
  • ¾÷°è Àü¹®°¡ÀÇ ½ÃÁ¡
  • ¾Ö³Î¸®½ºÆ®ÀÇ °á·Ð¡¤Á¦¾È

Á¦5Àå ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : Á¦Ç° À¯Çüº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : Á¦Ç° À¯Çüº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : Á¦Ç° À¯Çüº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • À§Ç³¼± ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ½Ì±Û
    • µà¾ó
    • Æ®¸®ÇÃ

Á¦6Àå ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : Åõ¿© ¹æ¹ýº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : Åõ¿©º°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ À§Ç³¼± ½ÃÀå, Åõ¿©¹ýº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • À§Ç³¼± ½ÃÀå, ÇÏÀ§ ºÎ¹®º° ºÐ¼®
    • ÇÊ
    • ³»½Ã°æ

Á¦7Àå ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : ÃæÀü Àç·áº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : ÃæÀü Àç·áº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : ÃæÀü Àç·áº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • À§Ç³¼± ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • »ý¸®½Ä¿°¼ö ÃæÀü
    • °¡½º ÃæÀü

Á¦8Àå À§Ç³¼± ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°

  • ½ÃÀå ½º³À¼ô
  • ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°, ½ÇÀû - ÀáÀç·Â ºÐ¼®
  • ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº° ÃßÁ¤¡¤¿¹Ãø 2020-2030³â
  • À§Ç³¼± ½ÃÀå, ÇÏÀ§ ºÎ¹® ºÐ¼®
    • º´¿ø°ú Áø·á¼Ò
    • ¿Ü·¡ ¿Ü°ú ¼¾ÅÍ
    • ±âŸ

Á¦9Àå ¼¼°èÀÇ À§Ç³¼± ½ÃÀå : Áö¿ªº° ºÐ¼®

  • ÁÖ¿ä ±¹°¡
  • ÁÖ¿ä ½ÅÈï ±¹°¡
  • À§Ç³¼± ½ÃÀå, Áö¿ªº° ½ÃÀå ½º³À¼ô
  • ºÏ¹Ì
    • ¹Ì±¹
      • Á¦Ç° À¯Çü ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • Åõ¿©¹ý ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ÃæÀü Àç·áº° ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
      • ÃÖÁ¾»ç¿ëÀÚÀÇ ÃßÁ¤¡¤¿¹Ãø, 2020-2030³â
    • ij³ª´Ù
  • À¯·´ À§Ç³¼± ½ÃÀå ½º³À¼ô
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç À§Ç³¼± ½ÃÀå ½º³À¼ô
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«ÀÇ À§Ç³¼± ½ÃÀå ½º³À¼ô
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï Á¤º¸

  • ÁÖ¿ä ±â¾÷ÀÇ SWOT ºÐ¼®
  • ÁÖ¿ä ½ÃÀå Àü·«
  • ±â¾÷ °³¿ä
    • Allurion Technologies, Inc.(U.S.)
      • ÁÖ¿ä Á¤º¸
      • °³¿ä
      • À繫(µ¥ÀÌÅÍ ÀÔ¼ö°¡ °¡´ÉÇÑ °æ¿ì¸¸)
      • Á¦Ç° °³¿ä
      • ÃÖ±Ù µ¿Çâ
    • Apollo Endosurgery Inc.(U.S.)
    • ReShape Lifesciences, Inc.(U.S.)
    • Lexel SRL(Argentina)
    • Medispar NV(Belgium)
    • Endalis(France)
    • Districlass Medical(France)
    • Silimed Brazil(Brazil)
    • Suzhou Shenyun Medical Equipment Co., Ltd(China)

Á¦11Àå Á¶»ç ÇÁ·Î¼¼½º

  • Á¶»ç ÇÁ·Î¼¼½º
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • ºÐ¼®
    • ½ÃÀå ÃßÁ¤
    • °ËÁõ
    • ÃâÆÇ
  • Á¶»ç ¼Ó¼º
  • Á¶»ç ÀüÁ¦Á¶°Ç
KSA 24.05.03

Global Intragastric Balloon Market is valued at approximately USD 39.2 million in 2022 and is anticipated to grow with a healthy growth rate of more than 13.9% over the forecast period 2023-2030. The intragastric balloon is a medical device designed to aid in weight loss for individuals struggling with obesity. It is a soft silicone balloon inserted into the stomach through the mouth and filled with a sterile saline solution, creating a sensation of fullness, and reducing food intake. The procedure is minimally invasive and temporarily administered endoscopically. Also, the balloon encourages healthier eating habits and lifestyle changes, serving as a supportive measure under healthcare supervision. The rise in adoption of minimally invasive treatment, increasing approval for intragastric balloon, and soaring healthcare expenditure are the most prominent factors that are propelling the market demand across the globe. According to a study published by the National Center for Biotechnology Information (NCBI) in January 2023, intragastric balloons emerge as a minimally invasive solution in addressing the obesity crisis. The United States and European markets have approved multiple intragastric balloons, with criteria varying from a BMI of 30 to 35 kg/m^2 in the U.S. to 27 to 35 kg/m^2 in Europe.

In addition, the demand for intragastric balloon placement is rising due to its safety and cost-effectiveness compared to surgical alternatives. According tothe World Health Organization's (WHO),as of 2022, the global prevalence of obesity has reached concerning levels, with approximately 1 in 8 individuals worldwide living with obesity. The rates of adult obesity have more than doubled since 1990, while adolescent obesity has quadrupled during the same period. Among adults aged 18 years and older, around 2.5 billion were classified as overweight, with a staggering 890 million falling into the category of obesity. This represents 43% of adults being overweight and 16% living with obesity. Moreover, there were 37 million overweight children under the age of 5, and over 390 million children and adolescents aged 5-19 years were overweight, including 160 million who were living with obesity. These statistics highlight the urgent need for global efforts to address and combat the obesity epidemic across age groups.. Intragastric balloons are extensively utilized for obesity treatment, delivering effective outcomes. Accordingly, the rise in prevalence of obesity globally is anticipated to positively influence the market growth. Obesity is associated with various non-communicable diseases like cardiovascular diseases, diabetes, stroke, hypertension, and certain cancers, prompting governments worldwide to raise awareness about obesity management. This awareness campaign is expected to fuel the adoption of intragastric balloons. Moreover, the rise the advancements in balloon technology, as well as the growing emphasis on lifestyle-focused weight management presents various lucrative opportunities over the forecasting years. However, the complications and risks related to intragastric balloon procedure, along with the lack of reimbursement are hindering the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Intragastric Balloon Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the widespread prevalence of obesity, the presence of skilled professionals, and significant adoption of weight loss treatments. Additionally, the rising popularity and adoption of the intragastric balloon further bolster regional growth Whereas Asia Pacific is expected to grow at the highest CAGR over the forecast years. The expanding patient population, growing awareness among healthcare professionals and patients regarding new technologies, and the introduction of various weight loss programs are significantly propelling the market demand across the region. For instance. in July 2020, Allurion Technologies, Inc. announced that the company has extended its presence in Asia through the introduction of the Elipse- a Gastric Balloon weight loss program.

Major market players included in this report are:

  • Allurion Technologies, Inc. (U.S.)
  • Apollo Endosurgery Inc. (U.S.)
  • ReShape Lifesciences, Inc. (U.S.)
  • Spatz Medical (U.S.)
  • Lexel SRL (Argentina)
  • Medispar NV (Belgium)
  • Endalis (France)
  • Districlass Medical (France)
  • Silimed Brazil (Brazil)
  • Suzhou Shenyun Medical Equipment Co., Ltd (China)

Recent Developments in the Market:

  • In October 2023, Allurion achieved full patient enrollment for its AUDACITY trial. This pivotal study is specifically structured to endorse the U.S. FDA approval process for the gastric balloon developed by the company.
  • In September 2023, ReShape Lifesciences, Inc. initiated a royalty-bearing license agreement with Biorad Medisys, Pvt. Ltd. (Biorad) for the development, commercialization, and distribution of Obalon gastric balloons across Pakistan, India, Nepal, Sri Lanka, and other Asia Pacific countries. This strategic initiative aims to enhance the company's footprint in emerging markets.
  • In June 2023, Allurion announced the company's collaboration with Medtronic to expand its AI-powered weight loss program into Central and Eastern Europe and the Middle East & Africa (CEMA) regions. This initiative integrates the Allurion balloon procedure-less gastric balloon for weight loss with the Allurion Virtual Care Suite, offering a comprehensive solution for individuals seeking effective weight management.

Global Intragastric Balloon Market Report Scope:

  • Historical Data - 2020 - 2021
  • Base Year for Estimation - 2022
  • Forecast period - 2023-2030
  • Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered - Product Type, Administration, Filling Material, End-user, Region
  • Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope - Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product Type:

  • Single
  • Dual
  • Triple

By Administration:

  • Pill
  • Endoscopy

By Filling Material:

  • Saline-Filled
  • Gas-Filled

By End-user:

  • Hospitals & Clinics
  • Outpatient Surgical Centers
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1.Executive Summary

  • 1.1.Market Snapshot
  • 1.2.Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Million)
    • 1.2.1.Intragastric Balloon Market, by Region, 2020-2030 (USD Million)
    • 1.2.2.Intragastric Balloon Market, by Product Type, 2020-2030 (USD Million)
    • 1.2.3.Intragastric Balloon Market, by Administration, 2020-2030 (USD Million)
    • 1.2.4.Intragastric Balloon Market, by Filling Material, 2020-2030 (USD Million)
    • 1.2.5.Intragastric Balloon Market, by End-user, 2020-2030 (USD Million)
  • 1.3.Key Trends
  • 1.4.Estimation Methodology
  • 1.5.Research Assumption

Chapter 2.Global Intragastric Balloon Market Definition and Scope

  • 2.1.Objective of the Study
  • 2.2.Market Definition & Scope
    • 2.2.1.Industry Evolution
    • 2.2.2.Scope of the Study
  • 2.3.Years Considered for the Study
  • 2.4.Currency Conversion Rates

Chapter 3.Global Intragastric Balloon Market Dynamics

  • 3.1.Intragastric Balloon Market Impact Analysis (2020-2030)
    • 3.1.1.Market Drivers
      • 3.1.1.1.Increase in adoption of minimally invasive treatment
      • 3.1.1.2.Rising prevalence of obesity
    • 3.1.2.Market Challenges
      • 3.1.2.1.Complications and risks related to intragastric balloon procedure
      • 3.1.2.2.Lack of reimbursement
    • 3.1.3.Market Opportunities
      • 3.1.3.1.Rise the advancements in balloon technology
      • 3.1.3.2.Growing emphasis on lifestyle-focused weight management

Chapter 4.Global Intragastric Balloon Market Industry Analysis

  • 4.1.Porter's 5 Force Model
    • 4.1.1.Bargaining Power of Suppliers
    • 4.1.2.Bargaining Power of Buyers
    • 4.1.3.Threat of New Entrants
    • 4.1.4.Threat of Substitutes
    • 4.1.5.Competitive Rivalry
  • 4.2.Porter's 5 Force Impact Analysis
  • 4.3.PEST Analysis
    • 4.3.1.Political
    • 4.3.2.Economical
    • 4.3.3.Social
    • 4.3.4.Technological
    • 4.3.5.Environmental
    • 4.3.6.Legal
  • 4.4.Top investment opportunity
  • 4.5.Top winning strategies
  • 4.6.COVID-19 Impact Analysis
  • 4.7.Disruptive Trends
  • 4.8.Industry Expert Perspective
  • 4.9.Analyst Recommendation & Conclusion

Chapter 5.Global Intragastric Balloon Market, by Product Type

  • 5.1.Market Snapshot
  • 5.2.Global Intragastric Balloon Market by Product Type, Performance - Potential Analysis
  • 5.3.Global Intragastric Balloon Market Estimates & Forecasts by Product Type 2020-2030 (USD Million)
  • 5.4.Intragastric Balloon Market, Sub Segment Analysis
    • 5.4.1.Single
    • 5.4.2.Dual
    • 5.4.3.Triple

Chapter 6.Global Intragastric Balloon Market, by Administration

  • 6.1.Market Snapshot
  • 6.2.Global Intragastric Balloon Market by Administration, Performance - Potential Analysis
  • 6.3.Global Intragastric Balloon Market Estimates & Forecasts by Administration 2020-2030 (USD Million)
  • 6.4.Intragastric Balloon Market, Sub Segment Analysis
    • 6.4.1.Pill
    • 6.4.2.Endoscopy

Chapter 7.Global Intragastric Balloon Market, by Filling Material

  • 7.1.Market Snapshot
  • 7.2.Global Intragastric Balloon Market by Filling Material, Performance - Potential Analysis
  • 7.3.Global Intragastric Balloon Market Estimates & Forecasts by Filling Material 2020-2030 (USD Million)
  • 7.4.Intragastric Balloon Market, Sub Segment Analysis
    • 7.4.1.Saline-Filled
    • 7.4.2.Gas-Filled

Chapter 8.Intragastric Balloon Market, by End-user

  • 8.1.Market Snapshot
  • 8.2.Global Intragastric Balloon Market by End-user, Performance - Potential Analysis
  • 8.3.Global Intragastric Balloon Market Estimates & Forecasts by End-user 2020-2030 (USD Million)
  • 8.4.Intragastric Balloon Market, Sub Segment Analysis
    • 8.4.1.Hospitals & Clinics
    • 8.4.2.Outpatient Surgical Centers
    • 8.4.3.Others

Chapter 9.Global Intragastric Balloon Market, Regional Analysis

  • 9.1.Top Leading Countries
  • 9.2.Top Emerging Countries
  • 9.3.Intragastric Balloon Market, Regional Market Snapshot
  • 9.4.North America Intragastric Balloon Market
    • 9.4.1.U.S. Intragastric Balloon Market
      • 9.4.1.1.Product Type breakdown estimates & forecasts, 2020-2030
      • 9.4.1.2.Administration breakdown estimates & forecasts, 2020-2030
      • 9.4.1.3.Filling Material breakdown estimates & forecasts, 2020-2030
      • 9.4.1.4.End-user breakdown estimates & forecasts, 2020-2030
    • 9.4.2.Canada Intragastric Balloon Market
  • 9.5.Europe Intragastric Balloon Market Snapshot
    • 9.5.1.U.K. Intragastric Balloon Market
    • 9.5.2.Germany Intragastric Balloon Market
    • 9.5.3.France Intragastric Balloon Market
    • 9.5.4.Spain Intragastric Balloon Market
    • 9.5.5.Italy Intragastric Balloon Market
    • 9.5.6.Rest of Europe Intragastric Balloon Market
  • 9.6.Asia-Pacific Intragastric Balloon Market Snapshot
    • 9.6.1.China Intragastric Balloon Market
    • 9.6.2.India Intragastric Balloon Market
    • 9.6.3.Japan Intragastric Balloon Market
    • 9.6.4.Australia Intragastric Balloon Market
    • 9.6.5.South Korea Intragastric Balloon Market
    • 9.6.6.Rest of Asia Pacific Intragastric Balloon Market
  • 9.7.Latin America Intragastric Balloon Market Snapshot
    • 9.7.1.Brazil Intragastric Balloon Market
    • 9.7.2.Mexico Intragastric Balloon Market
  • 9.8.Middle East & Africa Intragastric Balloon Market
    • 9.8.1.Saudi Arabia Intragastric Balloon Market
    • 9.8.2.South Africa Intragastric Balloon Market
    • 9.8.3.Rest of Middle East & Africa Intragastric Balloon Market

Chapter 10.Competitive Intelligence

  • 10.1.Key Company SWOT Analysis
  • 10.2.Top Market Strategies
  • 10.3.Company Profiles
    • 10.3.1.Allurion Technologies, Inc. (U.S.)
      • 10.3.1.1.Key Information
      • 10.3.1.2.Overview
      • 10.3.1.3.Financial (Subject to Data Availability)
      • 10.3.1.4.Product Summary
      • 10.3.1.5.Recent Developments
    • 10.3.2.Apollo Endosurgery Inc. (U.S.)
    • 10.3.3.ReShape Lifesciences, Inc. (U.S.)
    • 10.3.4.Lexel SRL (Argentina)
    • 10.3.5.Medispar NV (Belgium)
    • 10.3.6.Endalis (France)
    • 10.3.7.Districlass Medical (France)
    • 10.3.8.Silimed Brazil (Brazil)
    • 10.3.9.Suzhou Shenyun Medical Equipment Co., Ltd (China)

Chapter 11.Research Process

  • 11.1.Research Process
    • 11.1.1.Data Mining
    • 11.1.2.Analysis
    • 11.1.3.Market Estimation
    • 11.1.4.Validation
    • 11.1.5.Publishing
  • 11.2.Research Attributes
  • 11.3.Research Assumption
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦